SFM
IMVT icon

Soros Fund Management’s Immunovant IMVT Stock Holding History

Soros Fund Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-140,000
Closed -$5.9M – 221
2023
Q4 		$5.9M Buy
140,000
+65,000
+87% +$2.39M 0.08% 154
2023
Q3 		$2.88M Buy
+75,000
New +$1.7M 0.04% 187

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Soros Fund Management's IMVT Position: Q1 2024 in Review

Soros Fund Management sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 140,000 shares — an estimated $5.9M sold.

Soros Fund Management first reported a position in IMVT in Q3 2023 and held it in 2 quarters. The position peaked at $5.9M in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Soros Fund Management reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Soros Fund Management sold 140,000 Immunovant shares in Q1 2024, an estimated $5.9M.
  • Soros Fund Management first reported a position in Immunovant in Q3 2023 and held it in 2 quarters.
  • Soros Fund Management's Immunovant position peaked at $5.9M in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Soros Fund Management's 13F filing for Q1 2024, filed 15 May 2024.